<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02717884</url>
  </required_header>
  <id_info>
    <org_study_id>00806 UKF</org_study_id>
    <nct_id>NCT02717884</nct_id>
  </id_info>
  <brief_title>Study of Sensitization of Non-M3 AML Blasts to ATRA by Epigenetic Treatment With Tranylcypromine (TCP)</brief_title>
  <acronym>TRANSATRA</acronym>
  <official_title>Phase I/II Study of Sensitization of Non-M3 Acute Myeloid Leukemia (AML) Blasts to All-trans Retinoic Acid (ATRA) by Epigenetic Treatment With Tranylcypromine (TCP), an Inhibitor of the Histone Lysine Demethylase 1 (LSD1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Michael Luebbert</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital Freiburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Freiburg</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the phase I part of the trial is the determination of the maximum tolerated&#xD;
      dose (MTD) of TCP (Tranylcypromine) in combination with fixed-dose ATRA (all-trans-retinoic&#xD;
      acid) and with fixed-dose AraC (Cytarabine) and to derive the recommended phase II dose&#xD;
      (RP2D) in patients with non-APL AML or MDS for whom no standard treatment is available or who&#xD;
      failed azanucleoside treatment.&#xD;
&#xD;
      The objective of the phase II part of the trial is a first evaluation of the efficacy of TCP&#xD;
      at the RP2D in combination with fixed-dose ATRA and with fixed-dose AraC as basis for further&#xD;
      investigations of TCP&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study treatment: TCP + ATRA + AraC Four dose levels of TCP (20 mg, 40 mg, 60 mg, 80 mg on&#xD;
      days 1-28) will be examined in combination with fixed dose ATRA (45 mg/m2 on days 10-28) and&#xD;
      fixed-dose AraC (40 mg on days 1-10) in the first cycle.&#xD;
&#xD;
      In further cycles patients will be treated in the same manner, except for ATRA which will be&#xD;
      administered continuously with a nine-day interruption at the beginning of every fourth&#xD;
      cycle.&#xD;
&#xD;
      Follow-up per patient: Until twelve months after registration of the last patient.&#xD;
&#xD;
      Duration of intervention per patient: Until relapse/progression, unacceptable toxicity or&#xD;
      until twelve months after registration of the last patient, whatever occurs first&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MTD determination of TCP in combination with fixed-dose of ATRA and with fixed-dose Cytarabine;</measure>
    <time_frame>first 28 days of treatment</time_frame>
    <description>MTD determination of TCP in combination with fixed-dose of ATRA and with fixed-dose Cytarabine;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective best response</measure>
    <time_frame>through study completion, an average of one year</time_frame>
    <description>(CR complete remission, CRi complete remission with incomplete blood count recovery, PR partial remission)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>12 months</time_frame>
    <description>Overall survival (OS)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>TCP, ATRA, Cytarabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase I part:&#xD;
The rolling-six phase I design will be used to determine the MTD of TCP in combination with fixed-dose of ATRA and with fixed-dose AraC in patients with AML/MDS.&#xD;
Intervention: Four dose levels of TCP (20 mg, 40 mg**, 60 mg**, 80 mg** on days 1-28) will be examined in combination with ATRA (45 mg/m2 on days 10-28) and with fixed-dose AraC (40 mg on days 1-10) in the first cycle. In case of dose-limiting toxicity (DLT) on the starting level 1 of 20 mg a de-escalation to dose level of 10 mg (level -1) will be investigated.&#xD;
**TCP dose will be slowly increased to achieve the necessary dose level and slowly tapered off at the end of treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tranylcypromine</intervention_name>
    <description>TCP p.o., daily either 20, 40**, 60**, 80** mg/day, (28d/cycle)&#xD;
**TCP doses will be slowly increased during cycle 1 and slowly decreased at end of treatment (for details see study protocol)</description>
    <arm_group_label>TCP, ATRA, Cytarabine</arm_group_label>
    <other_name>TCP</other_name>
    <other_name>Jatrosom®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>all-trans retinoic acid</intervention_name>
    <description>45mg/m2 (days 10-28), CAVE: ATRA will be administered without interruption until inclusively cycle 3. At the beginning of the cycle 4 a nine-day break corresponding to the first nine days of the AraC treatment will be performed, thereafter the ATRA-therapy will be continued with a nine-day interruption every fourth cycle. That means that the therapy in cycles 1, 4, 7, 10, 13 etc. In other cycles ATRA will be given without interruption</description>
    <arm_group_label>TCP, ATRA, Cytarabine</arm_group_label>
    <other_name>ATRA</other_name>
    <other_name>Vesanoid®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
    <description>40mg s.c. (days 1-10)</description>
    <arm_group_label>TCP, ATRA, Cytarabine</arm_group_label>
    <other_name>Alexan®</other_name>
    <other_name>AraC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients eligible for inclusion in this trial must meet all of the following criteria:&#xD;
&#xD;
          1. Patients &gt;18 years (no upper age limit);&#xD;
&#xD;
          2. AML (WHO) or intermediate or higher risk MDS/ Chronic Myelomonocytic Leukemia (CMML)&#xD;
             (IPSS-R &gt;3.0);&#xD;
&#xD;
          3. No standard treatment available (comorbidities, higher age, refractoriness to standard&#xD;
             or salvage chemotherapy and allografting, azanucleosides failure*);&#xD;
&#xD;
          4. Patients with &lt; 30.000 leukocytes/µl;&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group (ECOG) 0,1,2;&#xD;
&#xD;
          6. Written informed consent obtained according to international guidelines and local&#xD;
             laws;&#xD;
&#xD;
          7. Ability to understand the nature of the trial and the trial related procedures and to&#xD;
             comply with them.&#xD;
&#xD;
               -  Azanucleosides failure is defined as 1) no response after at least three (AML) or&#xD;
                  six (MDS) cycles of azacitidine or decitabine, 2) disease progression under&#xD;
                  treatment or 3) grade 3-4 non-hematologic toxicity.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients eligible for this trial must not meet any of the following criteria:&#xD;
&#xD;
          1. Acute promyelocytic leukemia (APL, French-American-British classification system (FAB)&#xD;
             M3);&#xD;
&#xD;
          2. Eligibility for standard induction or consolidation chemotherapy, immediate&#xD;
             allografting, or a hypomethylating agent;&#xD;
&#xD;
          3. AML with central nervous system (CNS) involvement;&#xD;
&#xD;
          4. AraC treatment within one month prior to registration;&#xD;
&#xD;
          5. Prior exposure to histone deacetylase inhibitors, including sodium valproate within&#xD;
             one month prior to registration;&#xD;
&#xD;
          6. Stem cell transplant patient with graft-versus-host disease (GvHD) or under systemic&#xD;
             immunosuppression;&#xD;
&#xD;
          7. Previous gastrointestinal surgery that might interfere with drug absorption;&#xD;
&#xD;
          8. Pheochromocytoma;&#xD;
&#xD;
          9. Carcinoid tumor;&#xD;
&#xD;
         10. Confirmed or suspected cerebrovascular disease;&#xD;
&#xD;
         11. Vascular malformations including aneurysm;&#xD;
&#xD;
         12. Severe renal insufficiency;&#xD;
&#xD;
         13. Severe or poorly controlled hypertension;&#xD;
&#xD;
         14. Severe cardiovascular disease;&#xD;
&#xD;
         15. Hepatic insufficiency/liver disease;&#xD;
&#xD;
         16. Porphyria;&#xD;
&#xD;
         17. Diabetes insipidus;&#xD;
&#xD;
         18. History or presence of malignant hyperthermia;&#xD;
&#xD;
         19. Known psychiatric disorders;&#xD;
&#xD;
         20. Known allergy against soy beans or peanuts;&#xD;
&#xD;
         21. Known hypersensitivity to or intolerance of one of the trial drugs or its constituents&#xD;
             (e.g. lactose, corn starch, indigocarmine (TCP), corn starch (AraC), other retinoids&#xD;
             (ATRA));&#xD;
&#xD;
         22. Simultaneous intake of the prohibited medication, incl. linezolid, that is likely to&#xD;
             cause interactions (see detailed list study protocol);&#xD;
&#xD;
         23. Patients who refuse to follow study-specific dietary guidelines;&#xD;
&#xD;
         24. Known or persistent abuse of medication, drugs or alcohol;&#xD;
&#xD;
         25. Current or planned pregnancy, nursing period;&#xD;
&#xD;
         26. Failure to use safe methods of contraception;&#xD;
&#xD;
         27. Simultaneous participation in other interventional trials which could interfere with&#xD;
             this trial and/or participation before the end of a required restriction period;&#xD;
&#xD;
         28. Participation in a clinical trial within the last 30 days before the start of this&#xD;
             trial&#xD;
&#xD;
         29. Persons who are in a relationship of dependence/employment with the sponsor or the&#xD;
             investigator;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Lübbert, MD, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Center - University of Freiburg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Lübbert, MD, Prof.</last_name>
    <phone>+49 761 270</phone>
    <phone_ext>35340</phone_ext>
    <email>michael.luebbert@uniklinik-freiburg.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexandra Schulz, MSc</last_name>
    <phone>+49 761 270</phone>
    <phone_ext>36710</phone_ext>
    <email>alexandra.schulz@uniklinik-freiburg.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Wuerttemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alwin Krämer, MD, Prof.</last_name>
      <phone>+49 6221</phone>
      <phone_ext>5637750</phone_ext>
      <email>a.kraemer@Dkfz-Heidelberg.de</email>
    </contact>
    <contact_backup>
      <last_name>Anne-Marie Geueke</last_name>
      <phone>+49 6221</phone>
      <phone_ext>568006</phone_ext>
      <email>anne-marie.geueke@med.uni-heidelberg.de</email>
    </contact_backup>
    <investigator>
      <last_name>Alwin Krämer, MD,Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tilmann Bochtler, MD,PD Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Düsseldorf, Medical School Duesseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Kündgen, MD, PD Dr.</last_name>
      <phone>+49 211 811</phone>
      <phone_ext>6338</phone_ext>
      <email>kuendgen@med.uni-duesseldorf.de</email>
    </contact>
    <contact_backup>
      <last_name>Ulrike Spiegelberg</last_name>
      <phone>+49 211 811</phone>
      <phone_ext>7714</phone_ext>
      <email>spiegelberg@med.uni-duesseldorf.de</email>
    </contact_backup>
    <investigator>
      <last_name>Andrea Kündgen, MD, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ulrich Germing, MD, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt Main, Medical School Frankfurt</name>
      <address>
        <city>Frankfurt Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tobias Berg, MD, Dr.</last_name>
      <phone>+49 69 6301</phone>
      <phone_ext>84004</phone_ext>
      <email>tobias.berg@kgu.de</email>
    </contact>
    <contact_backup>
      <last_name>Gesine Bug, MD, PD Dr.</last_name>
      <phone>+49 69 6301</phone>
      <phone_ext>7369</phone_ext>
      <email>gesine.bug@kgu.de</email>
    </contact_backup>
    <investigator>
      <last_name>Tobias Berg, MD, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gesine Bug, MD, PD Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg, Medical School Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Lübbert, MD, Prof.</last_name>
      <phone>+49 761 270</phone>
      <phone_ext>35340</phone_ext>
      <email>michael.luebbert@uniklinik-freiburg.de</email>
    </contact>
    <contact_backup>
      <last_name>Alexandra Schulz, MSc</last_name>
      <phone>+49 761 270</phone>
      <phone_ext>36710</phone_ext>
      <email>alexandra.schulz@uniklinik-freiburg.de</email>
    </contact_backup>
    <investigator>
      <last_name>Ralph Wäsch, MD, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum München rechts der Isar, Medical School Munich rechts der Isar</name>
      <address>
        <city>München, Munich</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katharina Götze, MD, Prof.</last_name>
      <phone>+49 89 4140</phone>
      <phone_ext>5618</phone_ext>
      <email>katharina.goetze@mri.tum.de</email>
    </contact>
    <contact_backup>
      <last_name>Sandra Eckert</last_name>
      <phone>+49 89 4140</phone>
      <phone_ext>5637</phone_ext>
      <email>sandra.eckert@mri.tum.de</email>
    </contact_backup>
    <investigator>
      <last_name>Katharina Götze, MD, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mareike Verbeek, MD, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen, Medical School Tuebingen</name>
      <address>
        <city>Tübingen, Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helmut R Salih, MD, Prof.</last_name>
      <phone>+49 7071 29</phone>
      <phone_ext>83275</phone_ext>
      <email>helmut.salih@med.uni-tuebingen.de</email>
    </contact>
    <contact_backup>
      <last_name>Heinz Schwarz, SN</last_name>
      <phone>+49 7071 29</phone>
      <phone_ext>82883</phone_ext>
      <email>heinz.schwarz@med.uni-tuebingen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Helmut R Salih, MD, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marcus M Schittenhelm, MD, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>February 4, 2016</study_first_submitted>
  <study_first_submitted_qc>March 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2016</study_first_posted>
  <last_update_submitted>October 16, 2018</last_update_submitted>
  <last_update_submitted_qc>October 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Freiburg</investigator_affiliation>
    <investigator_full_name>Michael Luebbert</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <keyword>AML</keyword>
  <keyword>MDS</keyword>
  <keyword>relapsed</keyword>
  <keyword>trans-retinoic acid ATRA</keyword>
  <keyword>epigenetic treatment</keyword>
  <keyword>non-M3 AML blasts</keyword>
  <keyword>tranylcypromine TCP</keyword>
  <keyword>LSD1</keyword>
  <keyword>refractory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Tretinoin</mesh_term>
    <mesh_term>Tranylcypromine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

